ArticleHealth and quality of life outcomes2018
Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) adapted for use in adult patients: report from an initial validation study.
Article in Health and quality of life outcomes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04922736 (Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Redistribution of Gaze Patterns in Facial Localized Scleroderma Following Autologous Fat Transfer: An Eye-Tracking Study.Aesthetic plastic surgery · 2026Observational
- Comparative study between fractional COArchives of dermatological research · 2025Article
- Superb microvascular imaging for evaluating the activity of juvenile localised scleroderma: a preliminary study.European radiology · 2024Article
- Article
- Recent Advances in Treatment of Systemic Sclerosis and Morphea.American journal of clinical dermatology · 2024Review
- Intramuscular Polydeoxyribonucleotides in Fibrotic and Atrophic Localized Scleroderma: An Explorative Prospective Cohort Study.Biomedicines · 2023Article
- Serum Levels of Selected IL-1 Family Cytokines in Patients with Morphea.Journal of clinical medicine · 2022Article
- Usefulness of Dermoscopy in Localized Scleroderma (LoS, Morphea) Diagnosis and Assessment-Monocentric Cross-Sectional Study.Journal of clinical medicine · 2022Article
- Laser Therapy for the Treatment of Morphea: A Systematic Review of Literature.Journal of clinical medicine · 2021Review
- Prior elicitation of the efficacy and tolerability of Methotrexate and Mycophenolate Mofetil in Juvenile Localised Scleroderma.AMRC open research · 2021Article
- Narrow-Band Reflectance Spectrophotometry for the Assessment of Erythematous and Hyperpigmented Skin Lesions in Localized Scleroderma: A Preliminary Study.Clinical, cosmetic and investigational dermatology · 2021Article
- Health-related quality of life and its influencing factors in adult patients with localized scleroderma - a cross-sectional study.Health and quality of life outcomes · 2020Article
- Associations between Disease Activity/Severity and Damage and Health-Related Quality of Life in Adult Patients with Localized Scleroderma-A Comparison of LoSCAT and Visual Analogue Scales.Journal of clinical medicine · 2020Article
- Ultrasound Utility in the Management of Morphea: A Comprehensive Review.Indian dermatology online journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundLocalized scleroderma (LoS) affects both children and adults and is associated with permanent functional and cosmetic impairment, and reduced quality of life predominating in adults. The Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) is a clinical instrument designed to measure an activity and damage of LoS. It has been validated for use with pediatric LoS patients. This study assessed the validity and reliability of the LoSCAT adapted for use in adults.
methodsBefore the initiation of the study two examiners participated in an intensive training course carried out by an expert in LoS. Appendices describing each LoSCAT domain were prepared. Features determining disease activity and damage in adult LoS patients were identified to properly evaluate the physician (Phys) and patient (Pt) global assessment (GA) of disease activity (A)/severity (S) and damage (D), which were used to assess convergent validity of the LoSCAT. Correlations of physician- and patient-derivied measures with Skindex-29 were also analysed.
resultsThe study included 40 adult LoS patients (33 females and 7 males) with different subtypes of LoS. Intra and inter-rater reliability of the LoSCAT was found to be excellent. Positive correlations were observed between the PhysGA-A, PhysGA-D, PtGA-A and the LoSCAT's domains, while no correlations between them and the PtGA-D were found. There were no relationships between LoSCAT's components and Skindex-29.
conclusionsDespite the LoSCAT is a reliable tool for an assessment of cutaneous lesions, additional health status instruments are necessary to a holistic approach to LoS in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.